低剂量放疗抗肿瘤免疫应答的机制解析与临床进展
Mechanistic Analysis and Clinical Advances of Low-Dose Radiotherapy in Antitumor Immune Responses
DOI: 10.12677/acm.2026.1662435, PDF,   
作者: 付冬静, 李全福*:内蒙古医科大学鄂尔多斯临床医学院,内蒙古 鄂尔多斯;鄂尔多斯市中心医院肿瘤内科,内蒙古 鄂尔多斯;金高娃, 邓淑琴, 王文娟, 高佳丽, 达楞高娃, 乌云高娃, 韩亚龙, 田 丹:鄂尔多斯市中心医院肿瘤内科,内蒙古 鄂尔多斯
关键词: 低剂量放疗非小细胞肺癌免疫治疗免疫耐药Low-Dose Radiotherapy Non-Small Cell Lung Cancer Immunotherapy Immune Resistance
摘要: 放疗联合免疫治疗是解决免疫耐药问题的关键。常规放疗方式是被最广泛选择的,但是最近的研究表明,低剂量放疗(LDRT)在局部肿瘤控制方面更有效,正常组织毒性可以忽略不计。低剂量放疗(LDRT)调节肿瘤免疫微环境、增加T细胞的浸润与募集、诱导免疫反应,这些机制可能共同负责并参与局部肿瘤控制。本文重点介绍了LDRT的免疫刺激作用、临床疗效、安全性及其耐受性,同时也对LDRT的毒性进行了初步探讨。
Abstract: Radiotherapy combined with immunotherapy is key to overcoming immune resistance. Conventional radiotherapy remains the most widely adopted approach, but recent studies indicate that low-dose radiotherapy (LDRT) offers superior local tumor control with negligible normal tissue toxicity. Low-dose radiotherapy (LDRT) modulates the tumor immune microenvironment, enhances T-cell infiltration and recruitment, and induces immune responses. These mechanisms collectively contribute to and participate in local tumor control. This article highlights the immunostimulatory effects, clinical efficacy, safety, and tolerability of LDRT, while also providing preliminary insights into its toxicity.
文章引用:付冬静, 金高娃, 邓淑琴, 王文娟, 高佳丽, 达楞高娃, 乌云高娃, 韩亚龙, 田丹, 李全福. 低剂量放疗抗肿瘤免疫应答的机制解析与临床进展[J]. 临床医学进展, 2026, 16(6): 2148-2157. https://doi.org/10.12677/acm.2026.1662435

参考文献

[1] Bray, F., Laversanne, M., Weiderpass, E. and Soerjomataram, I. (2021) The Ever‐Increasing Importance of Cancer as a Leading Cause of Premature Death Worldwide. Cancer, 127, 3029-3030. [Google Scholar] [CrossRef] [PubMed]
[2] Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., et al. (2020) Updated Analysis from KEYNOTE-189: Pembrolizumab or Placebo plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517. [Google Scholar] [CrossRef] [PubMed]
[3] Mok, T.S.K., Wu, Y., Kudaba, I., Kowalski, D.M., Cho, B.C., Turna, H.Z., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, Pd-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. [Google Scholar] [CrossRef] [PubMed]
[4] Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., et al. (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients with Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of Keynote-407. Journal of Thoracic Oncology, 15, 1657-1669. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, D.S. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1-10. [Google Scholar] [CrossRef] [PubMed]
[6] Garcia‐Lora, A., Algarra, I. and Garrido, F. (2003) MHC Class I Antigens, Immune Surveillance, and Tumor Immune Escape. Journal of Cellular Physiology, 195, 346-355. [Google Scholar] [CrossRef] [PubMed]
[7] Labani-Motlagh, A., Ashja-Mahdavi, M. and Loskog, A. (2020) The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Frontiers in Immunology, 11, Article No. 940. [Google Scholar] [CrossRef] [PubMed]
[8] De Jaeghere, E.A., Denys, H.G. and De Wever, O. (2019) Fibroblasts Fuel Immune Escape in the Tumor Microenvironment. Trends in Cancer, 5, 704-723. [Google Scholar] [CrossRef] [PubMed]
[9] Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., et al. (2019) Role of the Tumor Microenvironment in PD-L1/PD-1-Mediated Tumor Immune Escape. Molecular Cancer, 18, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[10] Formenti, S.C. and Demaria, S. (2012) Radiation Therapy to Convert the Tumor into an in Situ Vaccine. International Journal of Radiation Oncology Biology Physics, 84, 879-880. [Google Scholar] [CrossRef] [PubMed]
[11] Herrera, F.G., Ronet, C., Ochoa de Olza, M., Barras, D., Crespo, I., Andreatta, M., et al. (2022) Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 12, 108-133. [Google Scholar] [CrossRef] [PubMed]
[12] Mavragani, I.V., Laskaratou, D.A., Frey, B., Candéias, S.M., Gaipl, U.S., Lumniczky, K., et al. (2015) Key Mechanisms Involved in Ionizing Radiation-Induced Systemic Effects. A Current Review. Toxicology Research, 5, 12-33. [Google Scholar] [CrossRef] [PubMed]
[13] Mavragani, I., Nikitaki, Z., Souli, M., Aziz, A., Nowsheen, S., Aziz, K., et al. (2017) Complex DNA Damage: A Route to Radiation-Induced Genomic Instability and Carcinogenesis. Cancers, 9, Article No. 91. [Google Scholar] [CrossRef] [PubMed]
[14] Heil, M. and Land, W.G. (2014) Danger Signals—Damaged-Self Recognition across the Tree of Life. Frontiers in Plant Science, 5, Article No. 578. [Google Scholar] [CrossRef] [PubMed]
[15] Dovedi, S.J., Cheadle, E.J., Popple, A.L., Poon, E., Morrow, M., Stewart, R., et al. (2017) Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-Cell Populations When Combined with PD-1 Blockade. Clinical Cancer Research, 23, 5514-5526. [Google Scholar] [CrossRef] [PubMed]
[16] Lussier, D.M., Alspach, E., Ward, J.P., Miceli, A.P., Runci, D., White, J.M., et al. (2021) Radiation-Induced Neoantigens Broaden the Immunotherapeutic Window of Cancers with Low Mutational Loads. Proceedings of the National Academy of Sciences, 118, e2102611118. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, Y., Xiang, Y., Xin, V.W., Wang, X., Peng, X., Liu, X., et al. (2020) Dendritic Cell Biology and Its Role in Tumor Immunotherapy. Journal of Hematology & Oncology, 13, Article No. 107. [Google Scholar] [CrossRef] [PubMed]
[18] Marciscano, A.E. and Anandasabapathy, N. (2021) The Role of Dendritic Cells in Cancer and Anti-Tumor Immunity. Seminars in Immunology, 52, Article ID: 101481. [Google Scholar] [CrossRef] [PubMed]
[19] Le Gall, C.M., Weiden, J., Eggermont, L.J. and Figdor, C.G. (2018) Dendritic Cells in Cancer Immunotherapy. Nature Materials, 17, 474-475. [Google Scholar] [CrossRef] [PubMed]
[20] Alloatti, A., Kotsias, F., Magalhaes, J.G. and Amigorena, S. (2016) Dendritic Cell Maturation and Cross‐Presentation: Timing Matters! Immunological Reviews, 272, 97-108. [Google Scholar] [CrossRef] [PubMed]
[21] Villadangos, J.A. and Schnorrer, P. (2007) Intrinsic and Cooperative Antigen-Presenting Functions of Dendritic-Cell Subsets in Vivo. Nature Reviews Immunology, 7, 543-555. [Google Scholar] [CrossRef] [PubMed]
[22] Chun, S.H., Park, G., Han, Y.K., Kim, S.D., Kim, J.S., Lee, C.G., et al. (2013) Effect of Low Dose Radiation on Differentiation of Bone Marrow Cells into Dendritic Cells. Dose-Response, 11, 12-41. [Google Scholar] [CrossRef] [PubMed]
[23] Lumniczky, K., Impens, N., Armengol, G., Candéias, S., Georgakilas, A.G., Hornhardt, S., et al. (2021) Low Dose Ionizing Radiation Effects on the Immune System. Environment International, 149, Article ID: 106212. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, S., Yu, H., He, R., Song, X., Chen, S., Yu, N., et al. (2019) Exposure to Low-Dose Radiation Enhanced the Antitumor Effect of a Dendritic Cell Vaccine. Dose-Response, 17, Article ID: 500665362. [Google Scholar] [CrossRef] [PubMed]
[25] Shigematsu, A., Adachi, Y., Koike-Kiriyama, N., Suzuki, Y., Iwasaki, M., Koike, Y., et al. (2007) Effects of Low-Dose Irradiation on Enhancement of Immunity by Dendritic Cells. Journal of Radiation Research, 48, 51-55. [Google Scholar] [CrossRef] [PubMed]
[26] Shastri, N., Cardinaud, S., Schwab, S.R., Serwold, T. and Kunisawa, J. (2005) All the Peptides That Fit: The Beginning, the Middle, and the End of the MHC Class I Antigen‐Processing Pathway. Immunological Reviews, 207, 31-41. [Google Scholar] [CrossRef] [PubMed]
[27] Lee, M.Y., Jeon, J.W., Sievers, C. and Allen, C.T. (2020) Antigen Processing and Presentation in Cancer Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e001111. [Google Scholar] [CrossRef] [PubMed]
[28] Axelrod, M.L., Cook, R.S., Johnson, D.B. and Balko, J.M. (2019) Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. Clinical Cancer Research, 25, 2392-2402. [Google Scholar] [CrossRef] [PubMed]
[29] Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., K.Wansley, E., et al. (2006) Radiation Modulates the Peptide Repertoire, Enhances MHC Class I Expression, and Induces Successful Antitumor Immunotherapy. The Journal of Experimental Medicine, 203, 1259-1271. [Google Scholar] [CrossRef] [PubMed]
[30] Liu, C., Suksanpaisan, L., Chen, Y., Russell, S.J. and Peng, K. (2013) Enhancing Cytokine-Induced Killer Cell Therapy of Multiple Myeloma. Experimental Hematology, 41, 508-517. [Google Scholar] [CrossRef] [PubMed]
[31] Raulet, D.H. and Vance, R.E. (2006) Self-Tolerance of Natural Killer Cells. Nature Reviews Immunology, 6, 520-531. [Google Scholar] [CrossRef] [PubMed]
[32] Liu, S., Jin, S., Liu, X. and Sun, Y. (2001) Role of CD28/B7 Costimulation and IL-12/IL-10 Interaction in the Radiation-Induced Immune Changes. BMC Immunology, 2, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[33] Liu, S. (2003) Nonlinear Dose-Response Relationship in the Immune System Following Exposure to Ionizing Radiation: Mechanisms and Implications. Nonlinearity in Biology, Toxicology, Medicine, 1, Article ID: 971641180. [Google Scholar] [CrossRef] [PubMed]
[34] Carmona-Rodríguez, L., Martínez-Rey, D., Mira, E. and Mañes, S. (2020) SOD3 Boosts T Cell Infiltration by Normalizing the Tumor Endothelium and Inducing Laminin-α4. OncoImmunology, 9, Article ID: 1794163. [Google Scholar] [CrossRef] [PubMed]
[35] Griffioen, A., Damen, C., Martinotti, S., et al. (1996) Endothelial Intercellular Adhesion Molecule-1 Expression Is Suppressed in Human Malignancies: The Role of Angiogenic Factors. Cancer Research, 56, 1111-1117.
[36] Barsoumian, H.B., Ramapriyan, R., Younes, A.I., Caetano, M.S., Menon, H., Comeaux, N.I., et al. (2020) Low-Dose Radiation Treatment Enhances Systemic Antitumor Immune Responses by Overcoming the Inhibitory Stroma. Journal for ImmunoTherapy of Cancer, 8, e000537. [Google Scholar] [CrossRef] [PubMed]
[37] Zhou, L., Zhang, X., Li, H., Niu, C., Yu, D., Yang, G., et al. (2018) Validating the Pivotal Role of the Immune System in Low‐Dose Radiation‐Induced Tumor Inhibition in Lewis Lung Cancer‐Bearing Mice. Cancer Medicine, 7, 1338-1348. [Google Scholar] [CrossRef] [PubMed]
[38] Yin, L., Xue, J., Li, R., Zhou, L., Deng, L., Chen, L., et al. (2020) Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients with Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 108, 212-224. [Google Scholar] [CrossRef] [PubMed]
[39] Du, J., Su, S., Li, H., Shao, J., Meng, F., Yang, M., et al. (2017) Low Dose Irradiation Increases Adoptive Cytotoxic T Lymphocyte Migration in Gastric Cancer. Experimental and Therapeutic Medicine, 14, 5711-5716. [Google Scholar] [CrossRef] [PubMed]
[40] Farooque, A., Mathur, R., Verma, A., Kaul, V., Bhatt, A.N., Adhikari, J.S., et al. (2011) Low-Dose Radiation Therapy of Cancer: Role of Immune Enhancement. Expert Review of Anticancer Therapy, 11, 791-802. [Google Scholar] [CrossRef] [PubMed]
[41] Kumari, A., Cacan, E., Greer, S.F. and Garnett-Benson, C. (2013) Turning T Cells on: Epigenetically Enhanced Expression of Effector T-Cell Costimulatory Molecules on Irradiated Human Tumor Cells. Journal for ImmunoTherapy of Cancer, 1, Article No. 17. [Google Scholar] [CrossRef] [PubMed]
[42] Tu, T.H., Kim, C., Nam‐Goong, I.S., Nam, C.W., Kim, Y., Goto, T., et al. (2015) 4‐1BBL Signaling Promotes Cell Proliferation through Reprogramming of Glucose Metabolism in Monocytes/Macrophages. The FEBS Journal, 282, 1468-1480. [Google Scholar] [CrossRef] [PubMed]
[43] Eun, S., Lee, S., Xu, Y. and Croft, M. (2015) 4-1BB Ligand Signaling to T Cells Limits T Cell Activation. The Journal of Immunology, 194, 134-141. [Google Scholar] [CrossRef] [PubMed]
[44] Sheard, M.A., Krammer, P.H. and Zaloudik, J. (1999) Fractionated γ-Irradiation Renders Tumour Cells More Responsive to Apoptotic Signals through CD95. British Journal of Cancer, 80, 1689-1696. [Google Scholar] [CrossRef] [PubMed]
[45] Waring, P. and Müllbacher, A. (1999) Cell Death Induced by the Fas/Fas Ligand Pathway and Its Role in Pathology. Immunology & Cell Biology, 77, 312-317. [Google Scholar] [CrossRef] [PubMed]
[46] Kojima, S., Ishida, H., Takahashi, M. and Yamaoka, K. (2002) Elevation of Glutathione Induced by Low-Dose Gamma Rays and Its Involvement in Increased Natural Killer Activity. Radiation Research, 157, 275-280. [Google Scholar] [CrossRef] [PubMed]
[47] Cheda, A., Wrembel-Wargocka, J., Lisiak, E., Nowosielska, E.M., Marciniak, M. and Janiak, M.K. (2004) Single Low Doses of X Rays Inhibit the Development of Experimental Tumor Metastases and Trigger the Activities of NK Cells in Mice. Radiation Research, 161, 335-340. [Google Scholar] [CrossRef] [PubMed]
[48] Yang, G., Kong, Q., Wang, G., Jin, H., Zhou, L., Yu, D., et al. (2014) Low-Dose Ionizing Radiation Induces Direct Activation of Natural Killer Cells and Provides a Novel Approach for Adoptive Cellular Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 29, 428-434. [Google Scholar] [CrossRef] [PubMed]
[49] Kojima, S., Nakayama, K. and Ishida, H. (2004) Low Dose γ-Rays Activate Immune Functions via Induction of Glutathione and Delay Tumor Growth. Journal of Radiation Research, 45, 33-39. [Google Scholar] [CrossRef] [PubMed]
[50] Sakaguchi, S. (2005) Naturally Arising Foxp3-Expressing CD25+CD4+ Regulatory T Cells in Immunological Tolerance to Self and Non-Self. Nature Immunology, 6, 345-352. [Google Scholar] [CrossRef] [PubMed]
[51] Valzasina, B., Piconese, S., Guiducci, C. and Colombo, M.P. (2006) Tumor-Induced Expansion of Regulatory T Cells by Conversion of CD4+CD25− Lymphocytes Is Thymus and Proliferation Independent. Cancer Research, 66, 4488-4495. [Google Scholar] [CrossRef] [PubMed]
[52] Kachikwu, E.L., Iwamoto, K.S., Liao, Y., DeMarco, J.J., Agazaryan, N., Economou, J.S., et al. (2011) Radiation Enhances Regulatory T Cell Representation. International Journal of Radiation Oncology Biology Physics, 81, 1128-1135. [Google Scholar] [CrossRef] [PubMed]
[53] Muroyama, Y., Nirschl, T.R., Kochel, C.M., Lopez-Bujanda, Z., Theodros, D., Mao, W., et al. (2017) Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunology Research, 5, 992-1004. [Google Scholar] [CrossRef] [PubMed]
[54] Liu, R., Xiong, S., Zhang, L. and Chu, Y. (2010) Enhancement of Antitumor Immunity by Low-Dose Total Body Irradiationis Associated with Selectively Decreasing the Proportion and Number of T Regulatorycells. Cellular & Molecular Immunology, 7, 157-162. [Google Scholar] [CrossRef] [PubMed]
[55] Wang, B., Li, B., Dai, Z., Ren, S., Bai, M., Wang, Z., et al. (2014) Low-Dose Splenic Radiation Inhibits Liver Tumor Development of Rats through Functional Changes in CD4+CD25+Treg Cells. The International Journal of Biochemistry & Cell Biology, 55, 98-108. [Google Scholar] [CrossRef] [PubMed]
[56] Chávez-Galán, L., Olleros, M.L., Vesin, D. and Garcia, I. (2015) Much More than M1 and M2 Macrophages, There Are Also CD169+ and TCR+ Macrophages. Frontiers in Immunology, 6, Article No. 263. [Google Scholar] [CrossRef] [PubMed]
[57] Sica, A. and Mantovani, A. (2012) Macrophage Plasticity and Polarization: In Vivo Veritas. Journal of Clinical Investigation, 122, 787-795. [Google Scholar] [CrossRef] [PubMed]
[58] Yang, D., Yang, L., Cai, J., Hu, X., Li, H., Zhang, X., et al. (2021) A Sweet Spot for Macrophages: Focusing on Polarization. Pharmacological Research, 167, Article ID: 105576. [Google Scholar] [CrossRef] [PubMed]
[59] Sica, A., Schioppa, T., Mantovani, A. and Allavena, P. (2006) Tumour-Associated Macrophages Are a Distinct M2 Polarised Population Promoting Tumour Progression: Potential Targets of Anti-Cancer Therapy. European Journal of Cancer, 42, 717-727. [Google Scholar] [CrossRef] [PubMed]
[60] Allavena, P., Sica, A., Garlanda, C. and Mantovani, A. (2008) The Yin‐Yang of Tumor‐Associated Macrophages in Neoplastic Progression and Immune Surveillance. Immunological Reviews, 222, 155-161. [Google Scholar] [CrossRef] [PubMed]
[61] De Palma, M. and Lewis, C.E. (2013) Macrophage Regulation of Tumor Responses to Anticancer Therapies. Cancer Cell, 23, 277-286. [Google Scholar] [CrossRef] [PubMed]
[62] Prakash, H., Klug, F., Nadella, V., Mazumdar, V., Schmitz-Winnenthal, H. and Umansky, L. (2016) Low Doses of Gamma Irradiation Potentially Modifies Immunosuppressive Tumor Microenvironment by Retuning Tumor-Associated Macrophages: Lesson from Insulinoma. Carcinogenesis, 37, 301-313. [Google Scholar] [CrossRef] [PubMed]
[63] Nadella, V., Singh, S., Jain, A., Jain, M., Vasquez, K.M., Sharma, A., et al. (2018) Low Dose Radiation Primed iNOS+ M1macrophages Modulate Angiogenic Programming of Tumor Derived Endothelium. Molecular Carcinogenesis, 57, 1664-1671. [Google Scholar] [CrossRef] [PubMed]
[64] Klug, F., Prakash, H., Huber, P.E., Seibel, T., Bender, N., Halama, N., et al. (2013) Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype That Orchestrates Effective T Cell Immunotherapy. Cancer Cell, 24, 589-602. [Google Scholar] [CrossRef] [PubMed]
[65] Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H.H., et al. (2008) Vascular Normalization in Rgs5-Deficient Tumours Promotes Immune Destruction. Nature, 453, 410-414. [Google Scholar] [CrossRef] [PubMed]
[66] Huang, Y., Kim, B.Y.S., Chan, C.K., Hahn, S.M., Weissman, I.L. and Jiang, W. (2018) Improving Immune-Vascular Crosstalk for Cancer Immunotherapy. Nature Reviews Immunology, 18, 195-203. [Google Scholar] [CrossRef] [PubMed]
[67] Grabham, P., Hu, B., Sharma, P. and Geard, C. (2011) Effects of Ionizing Radiation on Three-Dimensional Human Vessel Models: Differential Effects According to Radiation Quality and Cellular Development. Radiation Research, 175, 21-28. [Google Scholar] [CrossRef] [PubMed]
[68] Li, J., Zeng, Z., Wu, Q., Chen, J., Liu, X., Zhang, J., et al. (2021) Immunological Modulation of the Th1/Th2 Shift by Ionizing Radiation in Tumors (Review). International Journal of Oncology, 59, Article No. 50. [Google Scholar] [CrossRef] [PubMed]
[69] Yang, G., Li, W., Jiang, H., Liang, X., Zhao, Y., Yu, D., et al. (2016) Low‐Dose Radiation May Be a Novel Approach to Enhance the Effectiveness of Cancer Therapeutics. International Journal of Cancer, 139, 2157-2168. [Google Scholar] [CrossRef] [PubMed]
[70] Sonanini, D., Griessinger, C.M., Schörg, B.F., Knopf, P., Dittmann, K., Röcken, M., et al. (2021) Low-Dose Total Body Irradiation Facilitates Antitumoral Th1 Immune Responses. Theranostics, 11, 7700-7714. [Google Scholar] [CrossRef] [PubMed]
[71] Bent, R., Moll, L., Grabbe, S. and Bros, M. (2018) Interleukin-1 Beta—A Friend or Foe in Malignancies? International Journal of Molecular Sciences, 19, Article No. 2155. [Google Scholar] [CrossRef] [PubMed]
[72] Lödermann, B., Wunderlich, R., Frey, S., Schorn, C., Stangl, S., Rödel, F., et al. (2012) Low Dose Ionising Radiation Leads to a NF-κB Dependent Decreased Secretion of Active IL-1β by Activated Macrophages with a Discontinuous Dose-Dependency. International Journal of Radiation Biology, 88, 727-734. [Google Scholar] [CrossRef] [PubMed]
[73] Yu, N., Wang, S., Song, X., Gao, L., Li, W., Yu, H., et al. (2018) Low-Dose Radiation Promotes Dendritic Cell Migration and IL-12 Production via the ATM/NF-KappaB Pathway. Radiation Research, 189, 409-417. [Google Scholar] [CrossRef] [PubMed]
[74] Schmidt, C.S. and Mescher, M.F. (2002) Peptide Antigen Priming of Naive, but Not Memory, CD8 T Cells Requires a Third Signal That Can Be Provided by IL-12. The Journal of Immunology, 168, 5521-5529. [Google Scholar] [CrossRef] [PubMed]
[75] Frankenberger, B. and Schendel, D.J. (2012) Third Generation Dendritic Cell Vaccines for Tumor Immunotherapy. European Journal of Cell Biology, 91, 53-58. [Google Scholar] [CrossRef] [PubMed]
[76] Xu, L., Zou, C., Zhang, S., Chu, T.S.M., Zhang, Y., Chen, W., et al. (2022) Reshaping the Systemic Tumor Immune Environment (STIE) and Tumor Immune Microenvironment (TIME) to Enhance Immunotherapy Efficacy in Solid Tumors. Journal of Hematology & Oncology, 15, 1-30. [Google Scholar] [CrossRef] [PubMed]
[77] Casbon, A., Reynaud, D., Park, C., Khuc, E., Gan, D.D., Schepers, K., et al. (2015) Invasive Breast Cancer Reprograms Early Myeloid Differentiation in the Bone Marrow to Generate Immunosuppressive Neutrophils. Proceedings of the National Academy of Sciences, 112, E566-E575. [Google Scholar] [CrossRef] [PubMed]
[78] McCoy, D.E., Feo, T., Harvey, T.A. and Prum, R.O. (2018) Structural Absorption by Barbule Microstructures of Super Black Bird of Paradise Feathers. Nature Communications, 9, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[79] McAllister, S.S. and Weinberg, R.A. (2014) The Tumour-Induced Systemic Environment as a Critical Regulator of Cancer Progression and Metastasis. Nature Cell Biology, 16, 717-727. [Google Scholar] [CrossRef] [PubMed]
[80] Yu, Y., Fu, P., Jin, J., Gao, S., Wang, W., Machtay, M., et al. (2021) Impact of Effective Dose to Immune Cells (EDIC) on Lymphocyte Nadir and Survival in Limited-Stage SCLC. Radiotherapy and Oncology, 162, 26-33. [Google Scholar] [CrossRef] [PubMed]
[81] Xu, C., Jin, J., Zhang, M., Liu, A., Wang, J., Mohan, R., et al. (2020) The Impact of the Effective Dose to Immune Cells on Lymphopenia and Survival of Esophageal Cancer after Chemoradiotherapy. Radiotherapy and Oncology, 146, 180-186. [Google Scholar] [CrossRef] [PubMed]
[82] Savage, T., Pandey, S. and Guha, C. (2020) Postablation Modulation after Single High-Dose Radiation Therapy Improves Tumor Control via Enhanced Immunomodulation. Clinical Cancer Research, 26, 910-921. [Google Scholar] [CrossRef] [PubMed]
[83] Barsoumian, H.B., Sezen, D., Menon, H., Younes, A.I., Hu, Y., He, K., et al. (2022) High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses. Cancers, 14, Article No. 221. [Google Scholar] [CrossRef] [PubMed]
[84] Menon, H., Chen, D., Ramapriyan, R., Verma, V., Barsoumian, H.B., Cushman, T.R., et al. (2019) Influence of Low-Dose Radiation on Abscopal Responses in Patients Receiving High-Dose Radiation and Immunotherapy. Journal for ImmunoTherapy of Cancer, 7, Article No. 237. [Google Scholar] [CrossRef] [PubMed]
[85] Patel, R.R., He, K., Barsoumian, H.B., Chang, J.Y., Tang, C., Verma, V., et al. (2021) High-Dose Irradiation in Combination with Non-Ablative Low-Dose Radiation to Treat Metastatic Disease after Progression on Immunotherapy: Results of a Phase II Trial. Radiotherapy and Oncology, 162, 60-67. [Google Scholar] [CrossRef] [PubMed]
[86] Zhou, X., Zhou, L., Yao, Z., Huang, M., Gong, Y., Zou, B., et al. (2023) Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 29, 4098-4108. [Google Scholar] [CrossRef] [PubMed]